Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Revised Draft For Compounding Pharmacies Opens Door To Compounding For Office Use

Executive Summary

FDA’s revised draft guidance on GMPs for outsourcing pharmacy compounding operations responds to calls to allow the compounding of small quantities of drugs presumably for office use. The IACP applauds the move.
Advertisement

Related Content

US FDA Shuttering More Operations As User Fee Money Dwindles
FDA Works To Encourage Office-Use Compounding In Advance Of Legislation
Groups Say GMPs for Compounding Pharmacies are Unworkable
Sterile Compounders Would Get Tailored Manufacturing Regs If FDA Gets New Authority

Topics

Advertisement
UsernamePublicRestriction

Register

PS124442

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel